---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-000528"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2026-01-26T23:59:59+00:00"
generated_at: "2026-05-16T08:15:38.987106+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aethlon removes shareholder approval condition; pre-funded warrants immediately exercisable

## Summary
- Amendments to SPA and Pre-Funded Warrant remove Nasdaq 5635 shareholder approval requirement, effective Jan 22, 2026.
- Pre-funded warrants issued to Armistice Capital (institutional investor) are now immediately exercisable.
- No other terms of the original December 2025 agreements were changed.
- Company's common stock trades on Nasdaq under ticker AEMD.

## SEC filing metadata
- accession: 0001683168-26-000528
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2026-01-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316826000528/0001683168-26-000528-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316826000528/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-000528
- JSON: https://secwatch.observer/filing/0001683168-26-000528.json
- Plain text: https://secwatch.observer/filing/0001683168-26-000528.txt

## Key facts
- Material Agreements
  AETHLON MEDICAL INC amended Amendment to Pre-Funded Common Stock Purchase Warrant with institutional investor valued at Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa (effective 2026-01-22).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: institutional investor
  - Value: Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa
  - Effective: 2026-01-22
  source text: Also on January 22, 2026, the Company and the Purchaser entered into the Amendment to Pre-Funded Common Stock Purchase Warrant (the “PFW Amendment”). The PFW Amendment amends the terms of that certain Pre-Funded Common Stock Purchase Warrant by and between the Company and the Purchaser dated December 8, 2025 (the “Warrant”), as previously disclosed on the Current Report on Form 8-K filed by the Company on December 8, 2025. The PFW Amendment removed the requirement that Company obtain shareholder approval of issuance or exercise the pre-funded warrants under Nasdaq 5635 prior to those pre-funded warrants becoming exercisable. As a result, the pre-funded warrants are immediately exercisable.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882291/000168316826000528/0001683168-26-000528-index.htm
- Material Agreements
  AETHLON MEDICAL INC amended Amendment to Securities Purchase Agreement with institutional investor valued at Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa (effective 2026-01-22).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: institutional investor
  - Value: Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa
  - Effective: 2026-01-22
  source text: On January 22, 2026, Aethlon Medical, Inc. (the “Company”) and an institutional investor (the “Purchaser”) entered into the Amendment to Securities Purchase Agreement (the “SPA Amendment”). The SPA Amendment amends the terms of that certain Securities Purchase Agreement by and between the Company and the Purchaser dated December 5, 2025 (the “Securities Purchase Agreement”), as previously disclosed on the Current Report on Form 8-K filed by the Company on December 8, 2025. The SPA Amendment removed the requirement that Company obtain shareholder approval of issuance or exercise the pre-funded warrants under Nasdaq 5635 prior to those pre-funded warrants becoming exercisable. As a result, the pre-funded warrants are immediately exercisable. All other terms of the Securities Purchase Agreement remain unchanged.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882291/000168316826000528/0001683168-26-000528-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.